Population pharmacokinetics of arbekacin, vancomycin, and panipenem in Neonates

被引:69
|
作者
Kimura, T
Sunakawa, K
Matsuura, N
Kubo, H
Shimada, S
Yago, K
机构
[1] Kitasato Univ Hosp, Dept Pharm, Kanagawa 2288555, Japan
[2] Kitasato Univ Hosp, Div Neonatol, Kanagawa 2288555, Japan
[3] Kitasato Univ, Div Infect Dis, Sch Med, Kanagawa 2288555, Japan
[4] Kitasato Univ, Sch Pharmaceut Sci, Analyt Chem Lab, Minato Ku, Tokyo 1088641, Japan
关键词
D O I
10.1128/AAC.48.4.1159-1167.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Immature renal function in neonates requires antibiotic dosage adjustment. Population pharmacokinetic studies were performed to determine the optimal dosage regimens for three types of antibiotics: an aminoglycoside, arbekacin; a glycopeptide, vancomycin; and a carbapenem, panipenem. Eighty-three neonates received arbekacin (n=41), vancomycin (n=19), or panipenem (n=23). The postconceptional ages (PCAs) were 24.1 to 48.4 weeks, and the body weights (BWs) ranged from 458 to 5,200 g. A one-compartment open model with first-order elimination was applied and evaluated with a nonlinear mixed-effect model for population pharmacokinetic analysis. In the fitting process, the fixed effects significantly related to clearance (CL) were PCA, postnatal age, gestational age, BW, and serum creatinine level; and the fixed effect significantly related to the volume of distribution (V) was BW. The final formulas for the population pharmacokinetic parameters are as follows: CLarbekacin=0.0238 x BW/serum creatinine level for PCAs of <33 weeks and CLarbekacin=0.0367 x BW/serum creatinine level for PCAs of >= 33 weeks, V-arbekacin=0.54 liters/kg, CLvancomycin=0.0250 x BW/serum creatinine level for PCAs of <34 weeks and CLvancomycin=0.0323 x BW/serum creatinine level for PCAs of greater than or equal to34 weeks, V-vancomycin=0.66 liters/kg, CLpanipenem=0.0832 for PCAs of <33 weeks and CLpanipenem=0.179 x BW for PCAs of >= 33 weeks, and V-panipenem=0.53 liters/kg. When the CL of each drug was evaluated by the nonlinear mixed-effect model, we found that the mean CL for subjects with PCAs of <33 to 34 weeks was significantly smaller than those with PCAs of greater than or equal to33 to 34 weeks, and CL showed an exponential increase with PCA. Many antibiotics are excreted by glomerular filtration, and maturation of glomerular filtration is the most important factor for estimation of antibiotic clearance. Clinicians should consider PCA, serum creatinine level, BW, and chemical features when determining the initial antibiotic dosing regimen for neonates.
引用
收藏
页码:1159 / 1167
页数:9
相关论文
共 50 条
  • [41] Population pharmacokinetics of phenobarbital in neonates
    Guillaume, CPF
    Stolk, LML
    Degraeuwe, PLJ
    Beysens, AJMM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (01) : 132 - 132
  • [42] Population pharmacokinetics of vancomycin in Chinese infants
    Sheng, Xiao-yan
    Chen, Chao-yang
    Ma, Ling-yue
    Liu, Ya-ou
    Zhou, Ying
    Cui, Yi-min
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (07) : 558 - 566
  • [43] Population Pharmacokinetics of Vancomycin in Pregnant Women
    Goyal, Rahul K.
    Moffett, Brady S.
    Gobburu, Jogarao V. S.
    Al Mohajer, Mayar
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [44] Population Pharmacokinetics of Vancomycin in Thai Patients
    Purwonugroho, Tunggul Adi
    Chulavatnatol, Suvatna
    Preechagoon, Yupaporn
    Chindavijak, Busba
    Malathum, Kumthorn
    Bunuparadah, Pakwan
    SCIENTIFIC WORLD JOURNAL, 2012,
  • [45] Population pharmacokinetics of vancomycin in Jordanian patients
    Zalloum, Needa
    Saleh, Mohammad I.
    Al Haj, Mohannad
    Balbisi, Montaser
    Al-Ghazawi, Mutasim
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2018, 17 (02) : 351 - 358
  • [46] Population Pharmacokinetic Study of Vancomycin in Preterm Neonates
    Caceres Guido, Paulo
    Travaglianti, Monica
    Castro, Graciela
    Licciardone, Nieves
    Ferreyra, Oscar
    Vietri, Silvia
    Mato, Gabriel
    Niselman, Viviana
    Schaiquevich, Paula
    LATIN AMERICAN JOURNAL OF PHARMACY, 2015, 34 (01): : 124 - 133
  • [47] Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates
    Mulubwa, Mwila
    Griesel, Heletje Aletta
    Mugabo, Pierre
    Dippenaar, Ricky
    van Wyk, Lizelle
    DRUGS IN R&D, 2020, 20 (02) : 105 - 113
  • [48] PHARMACOKINETICS OF VANCOMYCIN IN NEONATES UNDERGOING EXTRACORPOREAL MEMBRANE-OXYGENATION
    AMAKER, RD
    DIPIRO, JT
    BHATIA, J
    PEDIATRIC RESEARCH, 1995, 37 (04) : A41 - A41
  • [49] Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates
    Mwila Mulubwa
    Heletje Aletta Griesel
    Pierre Mugabo
    Ricky Dippenaar
    Lizelle van Wyk
    Drugs in R&D, 2020, 20 : 105 - 113
  • [50] VANCOMYCIN PHARMACOKINETICS IN VERY LOW BIRTH-WEIGHT NEONATES
    LEONARD, MB
    KOREN, G
    STEVENSON, DK
    PROBER, CG
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1989, 8 (05) : 282 - 286